Affymax Announces Updates to Senior Leadership Team
PALO ALTO, Calif.--(BUSINESS WIRE)--
Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Christine
Conroy, Pharm.D., to senior vice president, Regulatory Affairs and
Quality Assurance, as well as Tim Varacek to vice president, Sales and
Account Management. The company also announced Robert F. Venteicher,
Ph.D., will retire as Affymax's senior vice president, technical
operations effective March 31, 2013.
"We have made remarkable strides with OMONTYS in the past year, securing
approval of this once-monthly erythropoiesis-stimulating agent and
supporting its successful launch," said John Orwin, chief executive
officer of Affymax. "Christine played a critical role in our successful
New Drug Application and regulatory review of OMONTYS and has
demonstrated continued leadership in Corporate Quality and Regulatory
Affairs as we transitioned to a commercial-stage company. On the
commercial front, Tim has been instrumental in forging timely
relationships with our key customers and leading our sales team in their
efforts. We are pleased to have Christine's and Tim's pertinent
experience and expertise on our senior management team."
Dr. Conroy had served as vice president, Corporate Quality and
Regulatory Affairs for Affymax since December 2011. She served as vice
president Regulatory Affairs and Clinical Quality Assurance from July
2007 to November 2011, and she held positions with increasing levels of
responsibility in Regulatory Affairs from October 2004 to July 2007.
Before joining Affymax, Dr. Conroy held various senior level positions
in the regulatory departments of Genitope Corporation and Roche Global
Development. She started her career in the pharmaceutical industry in
1989 at Syntex Laboratories, Inc. in the Medical Services Department.
She earned her Pharm.D. from the University of Kansas, School of
Pharmacy, and her B.S. in pharmacy from the University of Colorado,
School of Pharmacy.
Mr. Varacek had served as executive director, Sales and Account
Management for Affymax since April 2011. Prior to joining Affymax, he
served in various executive roles in Sales Management, and from January
2007 through March 2011 was responsible for managing national accounts
for Amgen's nephrology franchise. During his tenure at Amgen, he also
served in various management positions within Marketing and Sales
Operations. Prior to Amgen, Mr. Varacek held positions in Sales, Sales
Management and Sales Training at Bristol-Myers Squibb Inc. Mr. Varacek
earned a B.S. in Biology from Binghamton University.
John Orwin continued, "I would also like to thank Bob for his
significant contributions throughout his close to six year tenure with
the company. We wish him well in his retirement."
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company based in Palo Alto,
California. Affymax's mission is to discover, develop and deliver
innovative therapies that improve the lives of patients with kidney
disease and other serious and often life-threatening illnesses.
The company's first marketed product, OMONTYS® (peginesatide) Injection,
was approved by the U.S. Food and Drug Administration (FDA) in March
2012. For additional information, please visit www.affymax.com.
This release contains forward-looking statements, including
statements regarding the potential of OMONTYS, the continuation and
success of Affymax's collaboration with Takeda Pharmaceuticals U.S.A.,
Inc. and the commercialization of OMONTYS. Affymax's actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties, including
risks relating to the factors affecting the commercial potential of
OMONTYS, the continued safety and efficacy of OMONTYS, industry and
competitive environment, regulatory requirements by the FDA or
other regulatory authorities, including post-marketing studies, trials
and Risk Evaluation and Mitigation Strategy, the potential for
disruptions to supply, financing requirements and our ability to
access capital and other matters that are described in Affymax's
Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of
this release. Affymax undertakes no obligation to update any
forward-looking statement in this press release.
Sylvia Wheeler, 650-812-8861
Source: Affymax, Inc.
News Provided by Acquire Media
Close window | Back to top